Oncologic Hormonal Therapy

Mahahalagang Punto

• Ang hormonal therapy sa oncology ay sumusupil sa hormone-driven tumor growth sa halip na magpalit ng hormones.
• Ginagamit ang antiestrogens at SERDs para sa hormone-receptor-positive breast cancer.
• Pangunahing ginagamit ang aromatase inhibitors sa postmenopausal estrogen-receptor-positive breast cancer.
• Ginagamit ang antiandrogens sa prostate cancer at nangangailangan ng liver-toxicity monitoring.
• Contraindicated ang tamoxifen kapag may coumarin-type anticoagulants at sa mga pasyenteng may dating DVT o PE.
• Ang toremifene ay ER-targeted option para sa advanced breast-cancer pathways at may high-priority QT-prolongation/torsades warning.
• Madalas na pinapares ang bicalutamide sa LHRH/GnRH analog sa metastatic prostate-cancer pathways.

Mechanism at Classification

Umaasa ang hormone-dependent tumors sa estrogen o androgen signaling para sa proliferation. Sinusupil ng oncologic hormonal therapies ang signaling na ito sa pamamagitan ng receptor blockade o pagbabawas ng hormone production.

• Antiestrogens/SERDs: Hinaharangan o dina-downregulate ang estrogen receptors sa hormone-receptor-positive breast tumors.
• Aromatase inhibitors: Pinipigil ang peripheral conversion tungo sa estrogen sa pamamagitan ng pag-block ng aromatase sa adipose tissue.
• Antiandrogens: Hinaharangan ang androgen receptors sa prostate tumors.

Common Drugs

Class	Examples	Typical Use Pattern
Antiestrogens/SERDs	Tamoxifen, fulvestrant, elacestrant	Tamoxifen oral kadalasang hanggang humigit-kumulang 5 taon; fulvestrant IM loading kasunod ng buwanang maintenance
Aromatase inhibitors	Anastrozole, exemestane	Araw-araw na oral therapy sa postmenopausal ER-positive disease
Estrogen receptor modulators	Toremifene	60 mg PO araw-araw sa piling estrogen-receptor-positive advanced breast-cancer pathways
Antiandrogens	Flutamide, bicalutamide	Bicalutamide karaniwang 50 mg PO araw-araw kasabay ng LHRH/GnRH analog therapy sa metastatic prostate-cancer pathways

Nursing Considerations

• Kumpirmahin ang hormone-receptor context bago simulan ang therapy (halimbawa ER-positive breast disease).
• I-monitor ang CBC, electrolytes, renal at liver function tests, at bone-health surveillance ayon sa order.
• I-monitor ang thromboembolic cues (calf pain/swelling, chest pain, biglaang dyspnea), lalo na sa tamoxifen pathways.
• Para sa toremifene pathways, kumuha ng baseline at follow-up ECG at i-monitor ang potassium/magnesium status kapag clinically indicated.
• Para sa antiandrogen therapy, i-trend ang liver enzymes dahil clinically significant ang hepatotoxicity risk.
• Para sa bicalutamide pathways, i-monitor ang anticoagulation interaction risk (halimbawa Coumadin/warfarin pathways) at bleeding signals.
• I-monitor ang menopausal-type adverse effects at adherence barriers sa mahabang treatment duration.
• I-review ang QT-prolonging coprescriptions at interaction risks (halimbawa piling antiarrhythmics, strong CYP3A4 inducers, grapefruit products) bago mag-administer.

Adverse Effects at Contraindications

• Common effects: Hot flashes, fatigue, weight gain, sexual dysfunction, vaginal dryness, pagduduwal/pagsusuka, diarrhea.
• Bone effects: Maaaring pataasin ng aromatase inhibitors ang osteoporosis risk.
• Sex-hormone effects sa males: Maaaring mangyari ang gynecomastia at breast tenderness sa antiandrogen pathways.
• Tamoxifen contraindications: Dating DVT/PE at kasabay na paggamit ng coumarin-type anticoagulants.
• Toremifene concerns: QT prolongation, torsade de pointes risk, hypercalcemia, at mataas na thromboembolic/cardiovascular adverse-effect burden sa high-risk clients.
• Bicalutamide concerns: Mataas na liver enzymes at bihirang liver failure; contraindicated sa pagbubuntis at hindi indikado sa female clients.

Health Teaching

• I-report agad ang lagnat, calf pain/swelling, chest pain, shortness of breath, at lumalalang bone pain.
• Panatilihin ang hydration at sundin ang naka-iskedyul na follow-up labs/imaging.
• I-report ang tuloy-tuloy na mood changes, matinding pagkapagod, o hindi matanggap na vasomotor symptoms para ma-adjust ang treatment.
• Iwasan ang unsupervised na bagong supplements o medications dahil sa interaction risk.

Related Concepts

• breast-tumor-receptor-profiles - Tinutukoy ng receptor status ang benepisyo ng endocrine therapy.
• breast-cancer-care - Isinasama ang endocrine therapy sa pangmatagalang recurrence-risk reduction.
• prostate-cancer - Antiandrogen therapy sa prostate-cancer pathways.
• warfarin - Coumarin anticoagulant interaction at contraindication context kasama ng tamoxifen.

Self-Check

1. Bakit hindi epektibo ang antiestrogens sa hormone-receptor-negative breast cancer?
2. Aling mga pasyente ang karaniwang kandidato para sa aromatase inhibitor pathways?
3. Aling symptom cluster ang dapat mag-trigger ng agarang thromboembolism escalation habang nasa tamoxifen therapy?